Gilead Sciences' spending on research and development 2008-2023
Gilead Sciences spent some five billion U.S. dollars on research and development in 2023. The statistic illustrates Gilead Sciences' spending on research and development from 2008 to 2023. In 2023, Gilead Sciences shot to the public limelight over its drug remdesivir (brand name Veklury), which was trialed and later approved as a drug against COVID-19.